{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:46:18Z","timestamp":1776836778770,"version":"3.51.2"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccination through the upper respiratory tract is a promising strategy, and particulate antigens, such as antigens associated with nanoparticles, triggered a stronger immune response than the sole antigens. Cationic maltodextrin-based nanoparticles loaded with phosphatidylglycerol (NPPG) are efficient for intranasal vaccination but non-specific to trigger immune cells. Here we focused on phosphatidylserine (PS) receptors, specifically expressed by immune cells including macrophages, to improve nanoparticle targeting through an efferocytosis-like mechanism. Consequently, the lipids associated with NPPG have been substituted by PS to generate cationic maltodextrin-based nanoparticles with dipalmitoyl-phosphatidylserine (NPPS). Both NPPS and NPPG exhibited similar physical characteristics and intracellular distribution in THP-1 macrophages. NPPS cell entry was faster and higher (two times more) than NPPG. Surprisingly, competition of PS receptors with phospho-L-serine did not alter NPPS cell entry and annexin V did not preferentially interact with NPPS. Although the protein association is similar, NPPS delivered more proteins than NPPG in cells. On the contrary, the proportion of mobile nanoparticles (50%), the movement speed of nanoparticles (3\u2009\u00b5m\/5\u2009min), and protein degradation kinetics in THP-1 were not affected by lipid substitution. Together, the results indicate that NPPS enter cells and deliver protein better than NPPG, suggesting that modification of the lipids of cationic maltodextrin-based nanoparticles may be a useful strategy to enhance nanoparticle efficacy for mucosal vaccination.<\/jats:p>","DOI":"10.1515\/bmc-2022-0029","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T08:20:55Z","timestamp":1687940455000},"source":"Crossref","is-referenced-by-count":3,"title":["Dipalmitoyl-phosphatidylserine-filled cationic maltodextrin nanoparticles exhibit enhanced efficacy for cell entry and intracellular protein delivery in phagocytic THP-1 cells"],"prefix":"10.1515","volume":"14","author":[{"given":"Cl\u00e9ment","family":"Brinkhuizen","sequence":"first","affiliation":[{"name":"University Lille, Inserm, CHU Lille, U1286 - INFINITE \u2013 Institute for Translational Research in Inflammation , F-59000 Lille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Shapman","sequence":"additional","affiliation":[{"name":"University of Rouen Normandy, INSERM US 51, CNRS UAR 2026, HeRacLeS-PRIMACEN, Normandie Universit\u00e9 , 76000 Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Lebon","sequence":"additional","affiliation":[{"name":"University of Rouen Normandy, INSERM US 51, CNRS UAR 2026, HeRacLeS-PRIMACEN, Normandie Universit\u00e9 , 76000 Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magalie","family":"B\u00e9nard","sequence":"additional","affiliation":[{"name":"University of Rouen Normandy, INSERM US 51, CNRS UAR 2026, HeRacLeS-PRIMACEN, Normandie Universit\u00e9 , 76000 Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Tardivel","sequence":"additional","affiliation":[{"name":"University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS , F-59000 Lille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Dubuquoy","sequence":"additional","affiliation":[{"name":"University Lille, Inserm, CHU Lille, U1286 - INFINITE \u2013 Institute for Translational Research in Inflammation , F-59000 Lille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Galas","sequence":"additional","affiliation":[{"name":"University of Rouen Normandy, INSERM US 51, CNRS UAR 2026, HeRacLeS-PRIMACEN, Normandie Universit\u00e9 , 76000 Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolphe","family":"Carpentier","sequence":"additional","affiliation":[{"name":"University Lille, Inserm, CHU Lille, U1286 - INFINITE \u2013 Institute for Translational Research in Inflammation , F-59000 Lille , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"2025120518334318740_j_bmc-2022-0029_ref_001","doi-asserted-by":"crossref","unstructured":"Meenakshi S, Kumar VU, Dhingra S, Murti K. Nasal vaccine as a booster shot: A viable solution to restrict pandemic? Clin Exp Vaccine Res. 2022;11(2):184\u201392.","DOI":"10.7774\/cevr.2022.11.2.184"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_002","doi-asserted-by":"crossref","unstructured":"Bernocchi B, Carpentier R, Betbeder D. Nasal nanovaccines. Int J Pharm. 2017;530(1\u20132):128\u201338.","DOI":"10.1016\/j.ijpharm.2017.07.012"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_003","doi-asserted-by":"crossref","unstructured":"Huang J, Ding Y, Yao J, Zhang M, Zhang Y, Xie Z, et al. Nasal nanovaccines for SARS-CoV-2 to address COVID-19. Vaccines (Basel). 2022;10(3):405.","DOI":"10.3390\/vaccines10030405"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_004","unstructured":"Kravtzoff R, Betbeder D, Davrinche C, Vaz Santiago J, Lule J. Use of hydrophilic particles associated with antigens for preparing vaccine compositions. Patent WO\/2002\/034239; 2002."},{"key":"2025120518334318740_j_bmc-2022-0029_ref_005","doi-asserted-by":"crossref","unstructured":"Dombu C, Carpentier R, Betbeder D. Influence of surface charge and inner composition of nanoparticles on intracellular delivery of proteins in airway epithelial cells. Biomaterials. 2012;33(35):9117\u201326.","DOI":"10.1016\/j.biomaterials.2012.08.064"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_006","doi-asserted-by":"crossref","unstructured":"Paillard A, Passirani C, Saulnier P, Kroubi M, Garcion E, Benoit JP, et al. Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as \u2018stealth\u2019 cationic nanocarriers. Pharm Res. 2010;27(1):126\u201333.","DOI":"10.1007\/s11095-009-9986-z"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_007","doi-asserted-by":"crossref","unstructured":"Fasquelle F, Carpentier R, Demouveaux B, Desseyn JL, Betbeder D. Importance of the phospholipid core for mucin hydrogel penetration and mucosal cell uptake of maltodextrin nanoparticles. ACS Appl Bio Mater. 2020;3(9):5741\u20139.","DOI":"10.1021\/acsabm.0c00521"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_008","doi-asserted-by":"crossref","unstructured":"Bernocchi B, Carpentier R, Lantier I, Ducournau C, Dimier-Poisson I, Betbeder D. Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J Controlled Rel. 2016;232:42\u201350.","DOI":"10.1016\/j.jconrel.2016.04.014"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_009","doi-asserted-by":"crossref","unstructured":"Dimier-Poisson I, Carpentier R, N\u2019Guyen TT, Dahmani F, Ducournau C, Betbeder D. Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials. 2015;50:164\u201375.","DOI":"10.1016\/j.biomaterials.2015.01.056"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_010","doi-asserted-by":"crossref","unstructured":"Le MQ, Carpentier R, Lantier I, Ducournau C, Fasquelle F, Dimier-Poisson I, et al. Protein delivery by porous cationic maltodextrin-based nanoparticles into nasal mucosal cells: Comparison with cationic or anionic nanoparticles. Int J Pharm X. 2019;1:100001.","DOI":"10.1016\/j.ijpx.2018.100001"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_011","unstructured":"De Miguel I, Imbertie L, Betbeder D, Lescure F, Kravtzoff R. Amphilic and ionic polymer matrixes and derivatives thereof. Patent WO\/2001\/051090, 2001."},{"key":"2025120518334318740_j_bmc-2022-0029_ref_012","doi-asserted-by":"crossref","unstructured":"Le MQ, Ye L, Bernasconi V, Carpentier R, Fasquelle F, Lycke N, et al. Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine. Int J Pharm. 2020;582:119348.","DOI":"10.1016\/j.ijpharm.2020.119348"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_013","doi-asserted-by":"crossref","unstructured":"Le MQ, Carpentier R, Lantier I, Ducournau C, Dimier-Poisson I, Betbeder D. Residence time and uptake of porous and cationic maltodextrin-based nanoparticles in the nasal mucosa: Comparison with anionic and cationic nanoparticles. Int J Pharm. 2018;550(1\u20132):316\u201324.","DOI":"10.1016\/j.ijpharm.2018.08.054"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_014","doi-asserted-by":"crossref","unstructured":"Ducournau C, Nguyen TT, Carpentier R, Lantier I, Germon S, Precausta F, et al. Synthetic parasites: A successful mucosal nanoparticle vaccine against toxoplasma congenital infection in mice. Future Microbiol. 2017;12:393\u2013405.","DOI":"10.2217\/fmb-2016-0146"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_015","doi-asserted-by":"crossref","unstructured":"Ducournau C, Moire N, Carpentier R, Cantin P, Herkt C, Lantier I, et al. Effective nanoparticle-based nasal vaccine against latent and congenital toxoplasmosis in sheep. Front Immunol. 2020;11:2183.","DOI":"10.3389\/fimmu.2020.02183"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_016","doi-asserted-by":"crossref","unstructured":"Boada-Romero E, Martinez J, Heckmann BL, Green DR. The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol. 2020;21(7):398\u2013414.","DOI":"10.1038\/s41580-020-0232-1"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_017","doi-asserted-by":"crossref","unstructured":"Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ. The TIM gene family: Emerging roles in immunity and disease. Nat Rev Immunol. 2003;3(6):454\u201362.","DOI":"10.1038\/nri1111"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_018","doi-asserted-by":"crossref","unstructured":"DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YL, Lee HH, et al. T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918\u201330.","DOI":"10.4049\/jimmunol.0903059"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_019","doi-asserted-by":"crossref","unstructured":"Bonnardel J, Da Silva C, Henri S, Tamoutounour S, Chasson L, Montanana-Sanchis F, et al. Innate and adaptive immune functions of peyer\u2019s patch monocyte-derived cells. Cell Rep. 2015;11(5):770\u201384.","DOI":"10.1016\/j.celrep.2015.03.067"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_020","doi-asserted-by":"crossref","unstructured":"Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol. 2018;36:489\u2013517.","DOI":"10.1146\/annurev-immunol-042617-053010"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_021","doi-asserted-by":"crossref","unstructured":"Oliveira LG, Peron JPS. Viral receptors for flaviviruses: Not only gatekeepers. J Leukoc Biol. 2019;106(3):695\u2013701.","DOI":"10.1002\/JLB.MR1118-460R"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_022","doi-asserted-by":"crossref","unstructured":"Chua BA, Ngo JA, Situ K, Morizono K. Roles of phosphatidylserine exposed on the viral envelope and cell membrane in HIV-1 replication. Cell Commun Signal. 2019;17(1):132.","DOI":"10.1186\/s12964-019-0452-1"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_023","doi-asserted-by":"crossref","unstructured":"Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016;23(6):962\u201378.","DOI":"10.1038\/cdd.2016.11"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_024","doi-asserted-by":"crossref","unstructured":"Wanderley JLM, DaMatta RA, Barcinski MA. Apoptotic mimicry as a strategy for the establishment of parasitic infections: Parasite- and host-derived phosphatidylserine as key molecule. Cell Commun Signal. 2020;18(1):10.","DOI":"10.1186\/s12964-019-0482-8"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_025","doi-asserted-by":"crossref","unstructured":"Forrester MA, Wassall HJ, Hall LS, Cao H, Wilson HM, Barker RN, et al. Similarities and differences in surface receptor expression by THP-1 monocytes and differentiated macrophages polarized using seven different conditioning regimens. Cell Immunol. 2018;332:58\u201376.","DOI":"10.1016\/j.cellimm.2018.07.008"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_026","doi-asserted-by":"crossref","unstructured":"Salah N, Dubuquoy L, Carpentier R, Betbeder D. Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells. Int J Pharm X. 2022;4:100114.","DOI":"10.1016\/j.ijpx.2022.100114"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_027","doi-asserted-by":"crossref","unstructured":"Kurosaka K, Watanabe N, Kobayashi Y. Production of proinflammatory cytokines by phorbol myristate acetate-treated THP-1 cells and monocyte-derived macrophages after phagocytosis of apoptotic CTLL-2 cells. J Immunol. 1998;161(11):6245\u20139.","DOI":"10.4049\/jimmunol.161.11.6245"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_028","doi-asserted-by":"crossref","unstructured":"Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine. 2008;26(51):6555\u201363.","DOI":"10.1016\/j.vaccine.2008.09.057"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_029","doi-asserted-by":"crossref","unstructured":"Vanloubbeeck Y, Pichyangkul S, Bayat B, Yongvanitchit K, Bennett JW, Sattabongkot J, et al. Comparison of the immune responses induced by soluble and particulate plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine. 2013;31(52):6216\u201324.","DOI":"10.1016\/j.vaccine.2013.10.041"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_030","doi-asserted-by":"crossref","unstructured":"Deng L, Mohan T, Chang TZ, Gonzalez GX, Wang Y, Kwon YM, et al. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat Commun. 2018;9(1):359.","DOI":"10.1038\/s41467-017-02725-4"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_031","doi-asserted-by":"crossref","unstructured":"Bernasconi V, Bernocchi B, Ye L, Le MQ, Omokanye A, Carpentier R, et al. Porous nanoparticles with self-adjuvanting M2e-fusion protein and recombinant hemagglutinin provide strong and broadly protective immunity against influenza virus infections. Front Immunol. 2018;9:2060.","DOI":"10.3389\/fimmu.2018.02060"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_032","doi-asserted-by":"crossref","unstructured":"Castignolles N, Morgeaux S, Gontier-Jallet C, Samain D, Betbeder D, Perrin P. A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens. Vaccine. 1996;14(14):1353\u201360.","DOI":"10.1016\/S0264-410X(96)00043-6"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_033","doi-asserted-by":"crossref","unstructured":"von Hoegen P. Synthetic biomimetic supra molecular biovector (SMBV) particles for nasal vaccine delivery. Adv Drug Deliv Rev. 2001;51(1-3):113\u201325.","DOI":"10.1016\/S0169-409X(01)00175-2"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_034","doi-asserted-by":"crossref","unstructured":"De Miguel I, Ioualalen K, Bonnefous M, Peyrot M, Nguyen F, Cervilla M, et al. Synthesis and characterization of supramolecular biovector (SMBV) specifically designed for the entrapment of ionic molecules. Biochim Biophys Acta. 1995;1237(1):49\u201358.","DOI":"10.1016\/0005-2736(95)00079-I"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_035","doi-asserted-by":"crossref","unstructured":"Peyrot M, Sautereau AM, Rabanel JM, Nguyen F, Tocanne JF, Samain D. Supramolecular biovectors (SMBV): A new family of nanoparticulate drug delivery systems. Synthesis and structural characterization. Int J Pharm. 1994;102(1):25\u201333.","DOI":"10.1016\/0378-5173(94)90036-1"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_036","doi-asserted-by":"crossref","unstructured":"Davies SP, Reynolds GM, Stamataki Z. Clearance of apoptotic cells by tissue epithelia: A putative role for hepatocytes in liver efferocytosis. Front Immunol. 2018;9:44.","DOI":"10.3389\/fimmu.2018.00044"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_037","doi-asserted-by":"crossref","unstructured":"Seeberg JC, Loibl M, Moser F, Schwegler M, Buttner-Herold M, Daniel C, et al. Non-professional phagocytosis: A general feature of normal tissue cells. Sci Rep. 2019;9(1):11875.","DOI":"10.1038\/s41598-019-48370-3"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_038","doi-asserted-by":"crossref","unstructured":"Salik E, Tyorkin M, Mohan S, George I, Becker K, Oei E, et al. Antigen trafficking and accessory cell function in respiratory epithelial cells. Am J Respir Cell Mol Biol. 1999;21(3):365\u201379.","DOI":"10.1165\/ajrcmb.21.3.3529"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_039","doi-asserted-by":"crossref","unstructured":"McDougall CM, Blaylock MG, Douglas JG, Brooker RJ, Helms PJ, Walsh GM. Nasal epithelial cells as surrogates for bronchial epithelial cells in airway inflammation studies. Am J Respir Cell Mol Biol. 2008;39(5):560\u20138.","DOI":"10.1165\/rcmb.2007-0325OC"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_040","doi-asserted-by":"crossref","unstructured":"Jahnsen FL, Gran E, Haye R, Brandtzaeg P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. Am J Respir Cell Mol Biol. 2004;30(1):31\u20137.","DOI":"10.1165\/rcmb.2002-0230OC"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_041","doi-asserted-by":"crossref","unstructured":"Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 2000;405(6782):85\u201390.","DOI":"10.1038\/35011084"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_042","doi-asserted-by":"crossref","unstructured":"Liu M, Li Q, Liang L, Li J, Wang K, Li J, et al. Real-time visualization of clustering and intracellular transport of gold nanoparticles by correlative imaging. Nat Commun. 2017;8:15646.","DOI":"10.1038\/ncomms15646"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_043","doi-asserted-by":"crossref","unstructured":"Toshima JY, Toshima J, Kaksonen M, Martin AC, King DS, Drubin DG. Spatial dynamics of receptor-mediated endocytic trafficking in budding yeast revealed by using fluorescent alpha-factor derivatives. Proc Natl Acad Sci U S A. 2006;103(15):5793\u20138.","DOI":"10.1073\/pnas.0601042103"},{"key":"2025120518334318740_j_bmc-2022-0029_ref_044","doi-asserted-by":"crossref","unstructured":"Mao L, Chen Z, Wang Y, Chen C. Design and application of nanoparticles as vaccine adjuvants against human corona virus infection. J Inorg Biochem. 2021;219:111454.","DOI":"10.1016\/j.jinorgbio.2021.111454"}],"container-title":["Biomolecular Concepts"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2022-0029\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2022-0029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T19:06:25Z","timestamp":1764961585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2022-0029\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,31]]},"published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1515\/bmc-2022-0029"],"URL":"https:\/\/doi.org\/10.1515\/bmc-2022-0029","relation":{},"ISSN":["1868-503X"],"issn-type":[{"value":"1868-503X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"20220029"}}